MedTrace Logo

Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke

NCT06900725 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-04-02

No results posted yet for this study

Summary

This prospectively enrolled, pragmatic randomized trial aims to investigate whether very low dose edoxaban regimen (15 mg daily) achieves similar edoxaban concentrations as low dose edoxaban regimen (30 mg daily), while maintaining a comparable risk of clinical outcomes and reducing major bleeding in elderly patients with atrial fibrillation and a history of ischemic stroke or transient ischemic attack.

Conditions

Interventions

DRUG

edoxaban

edoxaban 15 mg daily will be administered to the patients as secondary stroke prevention.

DRUG

Edoxaban 30 mg

edoxaban 30 mg daily will be administered to the patients as secondary stroke prevention.

Sponsors & Collaborators

  • National Taiwan University Hospital, Yun-Lin Branch

    collaborator OTHER

  • National Taiwan University Hospital Hsin-Chu Branch

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06900725 on ClinicalTrials.gov